셀트리온 제약

We are dedicated to researching and developing innovative medicines to address unmet medical needs, with a focus on ADCs (Antibody-Drug Conjugates). ADCs are cutting-edge therapies that combine antibodies with potent anti-cancer agents to precisely target cancer cells. We integrate advanced biological technologies with chemical conjugation techniques to enhance drug specificity while minimizing side effects. Through meticulous design and analysis, we are building a differentiated ADC platform, striving to provide patients with new treatment options and improved outcomes.

We are dedicated to overcoming the limitations of existing medicines by developing new drugs that enhance patient convenience and therapeutic efficacy, providing differentiated treatment options. From formulation development to clinical entry, we optimize every stage of the process to accelerate commercialization. Our goal is to create improved drugs that deliver tangible value in clinical settings.

We research innovative delivery technologies that maximize drug absorption and therapeutic efficacy. By utilizing advanced Drug Delivery System (DDS) technologies such as nanoparticles, lipid nanoparticles (LNPs), and microspheres, we enhance drug persistence, improve targeting, and minimize side effects. Our goal is to develop differentiated delivery platforms that improve the efficacy of existing drugs and increase the success rates of new drug and vaccine development.